Communicate with Supplier? Supplier
Vicky Ms. Vicky
What can I do for you?
Chat Now
Chat Now Contact Supplier
Jinan Guoding Pharmaceutical Co.,Ltd



Entrectinib was approved for marketing in Japan on June 19, 2019, and was approved by the FDA on August 15, 2019 for the treatment of advanced recurrent solid tumors with positive neurotrophic tyrosine receptor kinase (NTRK) fusion Adults and children; and for the treatment of metastatic non-small cell lung cancer with mutations in the ROS1 gene. Entratinib is a new type of oral tyrosine kinase inhibitor (TKI) with central nervous system activity, targeted therapy for solid tumors carrying NTRK1/2/3, ROS1 and ALK gene fusion mutations. The only TRK inhibitor clinically proven to be effective against primary and metastatic CNS diseases, and has no adverse off-target activity.

We are a manufacturer of Entrectinib Intermediates and API,CAS:1108743-60-7,CAS:1034975-35-3,CAS:1034975-62-6,CAS:1108745-25-0,CAS:1108745-30-7; Our core business:CDMO for Pharmaceutical intermediates and API.

Jinan Guoding Pharmaceutical Co.,Ltd
Business Type:Manufacturer
Product Range:Custom Chemical Services , Organic Intermediate , Pharmaceutical
Products/Service:Praprofen Intermediates , Larotrectinib Intermediates , Entrectinib Intermediates , Repotrectinib Intermediates , Amenamevir Intermediates , Active Pharmaceutical Ingredient
Company Address:5F,Building G,Diya Shuangchuang Industrial Park,No.2566,Century Avenue,High-tech Zone,Jinan City,Shandong Province, Jinan, Shandong, China

Previous: Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity

Next: API Guang Zhou 2021

Related Products List




About Us